Impact Biomedicines' Series A Round

Impact Biomedicines raised a round of funding on October 13, 2017.

Impact Biomedicines is developing treatments for patients with complex cancers. The company's pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhi…

Articles about Impact Biomedicines' Series A Round: